Leading companies rely on the Simcyp Simulator for COVID-19 decision-making
Simcyp Simulator and COVID-19
The Simcyp PBPK Simulator is informing pivotal go/no go decisions, designing smarter trials, and targeting dose and regimen with regard to repurposed drugs for COVID-19:
COVID-19 Compound Files – Available Now
The population and compound files within the Simulator each have around 1,000 data items compiled and validated from literature review, laboratory data, and clinical performance. These data classes correspond to properties of (or values dependent on) a particular compound, and to data describing the demographic, physiology, genotypic and phenotypic characteristics of a specific ethnic or disease population with relevant inter-individual variability distributions.
Among the 100 or so compound files available for use in the Simulator are many that are being tested alone or in combination, for COVID-19 and other addressing other global health challenges.
That list is growing, as new therapies are identified. A partial list is as follows:
Yeo, K. et al., “Ivermectin is unlikely to be clinically efficacious against SARS-CoV-2,” Antiviral Research, April 2020
Smith, P. et al, “Dosing Will Be a Key Success Factor in Repurposing Antivirals for COVID-19”, British Journal of Clinical Pharmacology, April 17, 2020
Yeo, et al., “Simulating the impact of disease on plasma and lung exposure of chloroquine, hydroxychloroquine and azithromycin in COVID-19 patients: application of PBPK modelling,” submitted to Clinical Pharmacology & Therapeutics, April 2020
Gaohua L, et al., ‘Development of a Multicompartment Permeability‐Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs,’ Clinical Pharmacology & Therapeutics, Oct 2015
Laurens F.M. Verscheijden, et al. ‘Chloroquine dosing recommendations for pediatric COVID‐19 supported by modeling and simulation, Clinical Pharmacology & Therapeutics, April 22, 2020
Shelby, M et al., ‘Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective,’ Clinical Pharmacology & Therapeutics, July, 2018
Gardner, I et al. “New tools support developing better TB drugs,” Certara blog: “https://www.certara.com/2017/04/14/new-tools-support-developing-better-tb-drugs/?ap=PBPK&UTM_LeadSource=